{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_05",
        "affectedSection": "Section 1.3 - Schedule of Activities (SOA)",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated Schedule of Activities table with detailed visit windows and assessment timing"
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_05",
        "affectedSection": "Section 8.2.1 - Physical Examination",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Physical examination timing clarified with reference to Section 8.2.1"
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_05",
        "affectedSection": "Section 8.2.2 - Vital Signs",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Vital signs and resting O2 saturation requirements specified for SCCHN cohort"
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_05",
        "affectedSection": "Section 10.3 - Laboratory Assessments",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Laboratory assessment schedule updated including blood chemistry, hematology, coagulation, and blood typing interference test"
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_05",
        "affectedSection": "Section 8.1 - Disease Assessment",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Disease assessment imaging schedule specified for different tumor types (HCC, SCCHN, EOC, GBM)"
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_05",
        "reasonText": "Clarification of assessment schedules and visit windows for different tumor cohorts",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_05",
        "reasonText": "Specification of cohort-specific requirements (e.g., Cohort E evaluation exceptions, SCCHN-specific O2 saturation monitoring)",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_05",
        "reasonText": "Addition of blood typing interference test requirements due to isatuximab interference with blood compatibility testing",
        "category": "Safety",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_05",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3",
        "afterText": "Physical examination: X (<7days prior to first dose) during screening D-14 to D-1",
        "summary": "Clarified physical examination must be performed within 7 days prior to first dose during screening"
      },
      {
        "id": "change_2",
        "amendmentId": "amend_05",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3",
        "afterText": "Resting O2 saturation for SCCHN: X at screening and throughout treatment phase",
        "summary": "Added resting O2 saturation monitoring requirement specifically for SCCHN cohort"
      },
      {
        "id": "change_3",
        "amendmentId": "amend_05",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3",
        "afterText": "Blood Typing Interference Test: X at screening D-14 to D-1, Cycle 2 Day 1 only, and before each transfusion",
        "summary": "Specified blood typing interference test schedule including requirement before each transfusion"
      },
      {
        "id": "change_4",
        "amendmentId": "amend_05",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3",
        "afterText": "Pregnancy test: every 30Â±7 days until 5 months after last dose of study treatment during survival follow-up",
        "summary": "Extended pregnancy testing requirement to 5 months after last dose during survival follow-up"
      },
      {
        "id": "change_5",
        "amendmentId": "amend_05",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3",
        "afterText": "CT/MRI (for HCC, SCCHN, and EOC): X (Weeks 9, 18, 27, and then every 12 weeks); Brain MRI (for GBM only): X (Weeks 6, 12, 18, 24, and then every 9 weeks)",
        "summary": "Specified different imaging schedules for solid tumors versus GBM"
      },
      {
        "id": "change_6",
        "amendmentId": "amend_05",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3",
        "afterText": "c evaluation not applicable for Cohort E",
        "summary": "Added footnote clarifying that certain evaluations on D8 and D15 are not applicable for Cohort E"
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 3,
      "changeCount": 6
    }
  }
}